tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Travel

tanzania times : Latest News and In-depth Analysis
HomeTravel
Travel

Sep 2, 2026

Senegal and IMF agree new $2.2 billion loan programme

Senegal has reached an agreement with the International Monetary Fund on a new $2.2 billion debt programme, the financial institution said on Tuesday. An earlier agreement was suspended in 2024 after the discovery of underreported debt.

All News

Travel

Huawei Launches AI-Ready Data Storage for Carriers to Embrace AI

BARCELONA,Spain,March 4,2025-- At MWC 2025 Barcelona,Dr. Peter Zhou,President of Huawei Data Storage Product Line,delivered a keynote speech on AI-Ready Data Storage Accelerates Telco-to-Techco Transf

Mar 5, 2025

Travel

Starlab Advances to Full Development After Successfully Completing Key NASA Milestone

Full development of the Starlab space station begins following the successful completion of the PDR,ensuring a seamless transition of activity from the International Space Station to commercial desti

Mar 5, 2025

Travel

Property for Industry (PFI) Extends Partnership with Yardi

Industrial specialist to centralise document management and automate processes AUCKLAND,New Zealand,March 4,2025-- Property for Industry (PFI),a specialist in the industrial sector,has extended its p

Mar 5, 2025

Travel

Mass production of high-quality, self-standing, large-diameter single-crystal (111) diamond substrates within reach

Development of n-Type Diamonds for Practical Use in Diamond Semiconductors also Making Advances TOKYO,March 4,2025-- Orbray has developed production technology for the world\'s largest self-standing

Mar 5, 2025

Travel

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

MELBOURNE,Australia and INDIANAPOLIS,Ind.,March 4,2025-- Telix Pharmaceuticals Limited (ASX: TLX,Nasdaq: TLX,Telix,the Company) invites investors to join a webinar showcasing the Company\'s late-stag

Mar 5, 2025

Travel

Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2]

Mar 5, 2025

1 ... 67 68 69 70 71 72 73 ... 140